Concurrent Usage of Nivolumab and Platinum-based Chemotherapy before and after Surgery for Resectable Non–Small-Cell Lung Cancer
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on May 31st, 2024
|
Nivolumab is an monoclonal antibody that enhances the immune clearance of tumor cell by inhibiting the PD-1 receptor. Neoadjuvant usage of nivolumab and platinum-based chemotherapy had significantly reduced the risk of death and disease recurrence in patients with resectable non–small-cell lung cancer. As a result, a study investigated the perioperative usage of nivolumab, before and after surgery, can improve clinical outcome by neutralizing residual tumor cells and inhibiting micrometastasis.
The phase 3 clinical trial included a total of 461 patients who had been diagnosed with resectable non–small-cell lung cancer, between stage IIA and IIIB. Half of the population has squamous tissue tumors, and the other half has nonsquamous tumors. Before the surgery, the patients were randomly assigned to be treated with either placebo or 360 mg of nivolumab every 3 weeks for 4 cycles. Afterwards, the treatment was continued with placebo and a higher dose of 480 mg nivolumab every 4 weeks for 1 year. Concurrently, the patients were treated with chemotherapy based on the discretion of the physicians: approximately 20% received cisplatin, and around 80% were treated with carboplatin. After a median follow-up period of 25.4 months, the researchers observed that the usage of nivolumab reduced the risk of disease recurrence and death by 42%. In addition, the odds of completed residue tumor elimination is 6 times higher in the nivolumab group.
The phase 3 clinical trial included a total of 461 patients who had been diagnosed with resectable non–small-cell lung cancer, between stage IIA and IIIB. Half of the population has squamous tissue tumors, and the other half has nonsquamous tumors. Before the surgery, the patients were randomly assigned to be treated with either placebo or 360 mg of nivolumab every 3 weeks for 4 cycles. Afterwards, the treatment was continued with placebo and a higher dose of 480 mg nivolumab every 4 weeks for 1 year. Concurrently, the patients were treated with chemotherapy based on the discretion of the physicians: approximately 20% received cisplatin, and around 80% were treated with carboplatin. After a median follow-up period of 25.4 months, the researchers observed that the usage of nivolumab reduced the risk of disease recurrence and death by 42%. In addition, the odds of completed residue tumor elimination is 6 times higher in the nivolumab group.